DXPE Heads Into Q2 Print With Bullish Options Tilt and Insider Selling Overhang

DXP Enterprises reports Q2 results today with options traders tilting notably bullish — but a persistent wave of insider selling since April raises a pointed question about how much confidence sits at the top of the house.

The options market is leaning toward upside into the print. The put/call ratio has dropped to 0.66, more than one standard deviation below its 20-day average of 0.80, meaning call demand is running well ahead of typical levels. That's a meaningful shift from late July, when the PCR briefly touched its 52-week high near 1.01 — the market's most defensive posture of the past year — and has since reversed sharply as the stock climbed. DXPE has gained nearly 5% on the day and 8% over the past month, closing at $170.98. The borrow market offers no friction to either side: availability is essentially unlimited, with over 3,000% of short interest available to lend, and cost to borrow has eased to just 0.35% — down roughly 30% over the past month. Short interest itself is a non-story at 2.2% of the float and falling, trimmed about 8% over the past month.

The insider picture tells a more cautious story. Every transaction in the recent trade record is a sale. The most significant came on April 8, when Chairman, President and CEO David Little sold 22,500 shares for over $3.1 million — joined the same day by the CFO, CIO, and Chief Accounting Officer in coordinated disposals. The Chief Marketing Officer followed in June, selling 10,000 shares at $164.37 for $1.6 million. Net insider selling totals roughly $9.2 million over the past 90 days. The largest institutional holder, FMR LLC, added aggressively — 585,000 shares in the most recent filing — partially offsetting the insider outflows, but Wellington Management trimmed by 252,000 shares and Wasatch Advisors cut its position by 188,000.

The bull case rests on a growth story that has been genuinely impressive. A prior ORTEX note flagged a 5-year EBIT CAGR above 46% and consistent double-digit annual sales growth, with the ORTEX stock score running near 80 — driven primarily by momentum and growth factor strength. The bear case is valuation: the stock's price-to-FCF ratio above 82 leaves little room for a disappointing print, and the consensus mean price target of $158.50 — struck in May — now sits roughly 7% below the current price of $170.98. The only recent analyst action of note was a downgrade to Hold by Freedom Broker in May, which accompanied a modest target raise to $157. There are no bellwether-firm moves on record recently enough to be reliable.

History adds one sharp data point. Last quarter's print triggered a roughly 14% one-day decline and a 16% five-day loss — the most severe recent earnings reaction in the dataset. The Q2 report will therefore test whether the stock's 43% year-to-date rally and the recent bullish options rotation reflect genuine conviction about the revenue and margin trajectory, or simply momentum chasing ahead of a result that has a demonstrated history of disappointing.